Immune effector cell-associated enterocolitis following chimeric antigen receptor T-cell therapy in multiple myeloma
Blood Cancer Journal2024cited by 49position: middledoi
Updated Safety and Efficacy Results of Abbv-383, a BCMA x CD3 Bispecific T-Cell Redirecting Antibody, in a First-in-Human Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma